NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Price, News & Analysis $1.20 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.24 +0.04 (+2.92%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PDS Biotechnology Stock (NASDAQ:PDSB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PDS Biotechnology alerts:Sign Up Key Stats Today's Range$1.18▼$1.2850-Day Range$0.54▼$1.4352-Week Range$0.51▼$1.92Volume1.17 million shsAverage Volume988,910 shsMarket Capitalization$66.98 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview PDS Biotechnology Group, Inc. is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials. Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform. The company’s research initiatives include both off‐the‐shelf vaccines targeting shared tumor antigens and personalized approaches that present patient‐specific neoantigens. By integrating novel adjuvant technology with established cancer targets, PDS Biotechnology aims to generate durable T-cell responses and improve clinical outcomes in multiple solid tumor indications. Founded in 2007 and headquartered in San Diego, California, PDS Biotechnology conducts its research, translational studies, and early clinical development across facilities in the United States. The company partners with academic centers and biopharmaceutical organizations to advance its product candidates through global clinical trials. Under the leadership of CEO Bruce D. Montgomery and an experienced management team, PDS Biotechnology is dedicated to translating its platform innovations into next-generation immunotherapies for patients with cancer and chronic viral infections.AI Generated. May Contain Errors. Read More PDS Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScorePDSB MarketRank™: PDS Biotechnology scored higher than 70% of companies evaluated by MarketBeat, and ranked 218th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPDS Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPDS Biotechnology has a consensus price target of $9.00, representing about 650.0% upside from its current price of $1.20.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about PDS Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PDS Biotechnology are expected to grow in the coming year, from ($0.52) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 17.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PDS Biotechnology's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.45% of the float of PDS Biotechnology has been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PDS Biotechnology has recently decreased by 0.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.00 News SentimentPDS Biotechnology has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.Search Interest31 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 244% compared to the previous 30 days.MarketBeat Follows10 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders9.20% of the stock of PDS Biotechnology is held by insiders.Percentage Held by Institutions26.84% of the stock of PDS Biotechnology is held by institutions.Read more about PDS Biotechnology's insider trading history. Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PDSB Stock News HeadlinesPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comPDS Biotechnology Q1 2026 Earnings Call: Complete TranscriptMay 15, 2026 | finance.yahoo.comThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.May 26 at 1:00 AM | Behind the Markets (Ad)PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 15, 2026 | finance.yahoo.comPDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical UpdateMay 13, 2026 | quiverquant.comQPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | markets.businessinsider.comPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6, 2026 | globenewswire.comSee More Headlines PDSB Stock Analysis - Frequently Asked Questions How have PDSB shares performed this year? PDS Biotechnology's stock was trading at $0.7698 on January 1st, 2026. Since then, PDSB stock has increased by 55.9% and is now trading at $1.20. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Corporation (NASDAQ:PDSB) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. Read the conference call transcript. When did PDS Biotechnology IPO? PDS Biotechnology (PDSB) raised $110 million in an IPO on Thursday, October 1st 2015. The company issued 7,315,151 shares at $14.00-$16.00 per share. Who are PDS Biotechnology's major shareholders? PDS Biotechnology's top institutional investors include Renaissance Technologies LLC (0.41%). View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2026Today5/26/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PDSB's financial health is in the Green zone, according to TradeSmith. PDSB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PDSB CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees20Year Founded2005Price Target and Rating Average Price Target for PDS Biotechnology$9.00 High Price Target$15.00 Low Price Target$3.00 Potential Upside/Downside+650.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-346.02% Return on Assets-102.36% Debt Debt-to-Equity Ratio2.73 Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book17.14Miscellaneous Outstanding Shares55,820,000Free Float50,681,000Market Cap$66.98 million OptionableOptionable Beta1.51 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PDSB) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTim Plaehn's income ETF research is available at 82% off - but only until midnight tonight. This Memorial Day ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
